Amgen (AMGN) Change in Receivables (2009 - 2026)
Amgen (AMGN) posted quarterly Change in Receivables of -$413.0 million for Q1 2026, down 131.57% year-over-year from $1.3 billion in Q1 2025, and down 138.42% quarter-over-quarter from $1.1 billion in Q4 2025.
Amgen (AMGN) Change in Receivables (2009 - 2026) Analysis & Trends
Amgen's Change in Receivables history runs 18 years deep, the most recent figure standing at -$413.0 million for Q1 2026.
- In Q1 2026, Change in Receivables fell 131.57% year-over-year to -$413.0 million; the TTM figure through Mar 2026 stood at $955.0 million (down 29.42% YoY), while the FY2025 annual figure was $2.7 billion, up 706.8% from the prior year.
- Change in Receivables for Q1 2026 stood at -$413.0 million, down from $1.1 billion in the prior quarter.
- The five-year high for Change in Receivables was $1.3 billion in Q1 2025, with the low at -$486.0 million in Q1 2024.
- The 5-year median for Change in Receivables is $180.0 million (2022), against an average of $210.8 million.
- The sharpest annual moves came in 2022 and 2024: Change in Receivables soared 451.79% in 2022, then tumbled 437.5% in 2024.
- Amgen's Change in Receivables stood at $180.0 million in 2022, then surged by 140.56% to $433.0 million in 2023, then tumbled by 209.24% to -$473.0 million in 2024, then jumped by 327.27% to $1.1 billion in 2025, then plunged by 138.42% to -$413.0 million in 2026.
- Business Quant data shows AMGN's Change in Receivables at -$413.0 million in Q1 2026, $1.1 billion in Q4 2025, and -$222.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.09 Bn |
| Jun 30, 2026 | 1.09 Bn |
| Mar 31, 2026 | -413.00 Mn |
| Mar 31, 2026 | -413.00 Mn |
| Dec 31, 2025 | 1.08 Bn |
| Dec 31, 2025 | 1.08 Bn |
| Sep 30, 2025 | -222.00 Mn |
| Sep 30, 2025 | -222.00 Mn |
| Jun 30, 2025 | 515.00 Mn |
| Jun 30, 2025 | 515.00 Mn |
| Mar 31, 2025 | 1.31 Bn |
| Mar 31, 2025 | 1.31 Bn |
| Dec 31, 2024 | -473.00 Mn |
| Dec 31, 2024 | -473.00 Mn |
| Sep 30, 2024 | 342.00 Mn |
| Sep 30, 2024 | 342.00 Mn |
| Jun 30, 2024 | 176.00 Mn |
| Jun 30, 2024 | 176.00 Mn |
| Mar 31, 2024 | -486.00 Mn |
| Mar 31, 2024 | -486.00 Mn |